Real-world efficacy and safety profile of low-dose cadonilimab in recurrent or metastatic cervical cancer as first-line therapy.

Kaitanni (cadonilimab) - Akesobio

http://www.ncbi.nlm.nih.gov/pubmed/42682635

Can Zhang; Dengfeng Wang; Guonan Zhang; Jing Zheng; Liping Peng; Xiaoshi Liu; Xunwei Shi

Sep 3, 2026